Pembrolizumab
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-Naïve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)
ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merck’s Keytruda is ...
Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2– Breast Cancer Treatment (ESMO 2023)
ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
Pembrolizumab Frontline Use With Lenvatinib Supported in nccRCC
Combining pembrolizumab (Keytruda) with lenvatinib (Lenvima) has showcased enduring effectiveness against tumors in patients with non-clear cell renal cell carcinoma ...
Beginning of TNG260 and Pembrolizumab Study in Advanced Solid Tumors
The first patient has received a dose of TNG260 in combination with pembrolizumab (Keytruda) as part of a Phase I/II ...
EU CHMP Grants Favorable Opinion to Merck’s Keytruda Combination for HER2-Positive Advanced Gastric Cancer
Source – Merck A new hope for patients with advanced gastric or GEJ cancer that is positive for both HER2 ...
CHMP Backs Approval of Pembrolizumab Combination Therapy for HER2+ Gastric Cancer in the EU
Source – Merck A new combination therapy for patients with advanced gastric or GEJ cancer that is positive for both ...
Treatment for Advanced HNSCC With ASP-1929 and Anti-EGFR Therapy Is Effective
Source – Rakuten Medical Promising early results have been observed with ASP-1929, in combination with anti-PD-1 therapy, for patients with ...
